Health Gains by Using Natriuretic Peptides in Diagnosis, Prognosis and Treatment

References

• Davis M., Espiner E., Richards G., Billings J., Town I., Neill A. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440–444
   PubMed Web of Science ®Google Scholar
• Cowie M. R., Struthers A. D., Wood D. A., Coats A. J., Thompson S. G., Poole‐wilson P. A. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–1353
   PubMed Web of Science ®Google Scholar
• Dao Q., Krishnaswamy P., Kazanegra R., Harrison A., Amirnovin R., Lenert L. Utility of B‐type natriuretic peptide in the diagnosis of congestive heart failure in an urgent‐care setting. J Am Coll Cardiol 2001; 37: 379–385
   PubMed Web of Science ®Google Scholar
• Maisel A. S., Krishnaswamy P., Nowak R. M., Mccord J., Hollander J. E., Duc P. Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–167
   PubMed Web of Science ®Google Scholar
• Lainchbury J. G., Campbell E., Frampton C. M., Yandle T. G., Nicholls M. G., Richards A. M. Brain natriuretic peptide and N‐terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42: 728–735
   PubMed Web of Science ®Google Scholar
• Wright S. P., Doughty R. N., Pearl A., Gamble G. D., Whalley G. A., Walsh H. J. Plasma amino‐terminal brain natriuretic peptide and accuracy of heart failure diagnosis in primary care: a randomised controlled trial. J Am Coll Cardiol 2003; 42: 1793–1800
   PubMed Web of Science ®Google Scholar
• Mueller C., Scholer A., Laule‐kilian K., Martina B., Schindler C., Buser P. Use of B‐type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647–654
   PubMed Web of Science ®Google Scholar
• Richards A. M., Nicholls M. G., Yandle T. G., Frampton C., Espiner E. A., Turner J. G. Plasma N‐terminal pro‐brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921–1929
   PubMed Web of Science ®Google Scholar
• Richards A. M., Doughty R., Nicholls M. G., Macmahon S., Ikram H., Sharpe N. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999; 99: 786–792
   PubMed Web of Science ®Google Scholar
• Cheng V., Kazanagra R., Garcia A., Lenert L., Kirshnaswamy P., Gardetto N. A rapid bedside test for Btype peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386–391
   PubMed Web of Science ®Google Scholar
• Richards A. M., Doughty R., Nicholls M. G., Macmahon S., Sharpe N., Murphy J. Plasma N‐terminal probrain natriuretic peptide and adrenomedullin. Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2001; 37: 1781–1787
   PubMed Web of Science ®Google Scholar
• Anand I. S., Fisher L. D., Chiang Y‐T., Latini R., Masson S., Maggioni A. P. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val‐HeFT). Circulation 2003; 107: 1278–1283
   PubMed Web of Science ®Google Scholar
• Omland T., Aakvaag A., Bonarjee V. V. S., Caidahl K., Lie R. T., Nilsen D. W. T. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long‐term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N‐terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963–1969
   PubMed Web of Science ®Google Scholar
• Arakawa N., Nakamura M., Aoki H., Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 1996; 27: 1656–1661
   PubMed Web of Science ®Google Scholar
• De lemos J. A., Morrow D. A., Bentley J. H., Omland T., Sabatine M. S., Mccabe C. H. The prognostic value of B‐type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014–1021
   PubMed Web of Science ®Google Scholar
• Jernberg T., Stridsberg M., Venge P., Lindahl B. N‐terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST‐segment elevation. J Am Coll Cardiol 2002; 40: 437–445
   PubMed Web of Science ®Google Scholar
• Omland T., Persson A., Ng L., O'brien R., Karlsson T., Herlitz J. N‐terminal pro‐B‐type natriuretic peptide and long‐term mortality in acute coronary syndromes. Circulation 2002; 106: 2913–2918
   PubMed Web of Science ®Google Scholar
• Richards A. M., Nicholls M. G., Espiner E. A., Lainchbury J. G., Troughton R. W., Elliott J. B‐type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786–2792
   PubMed Web of Science ®Google Scholar
• Troughton R. W., Frampton C. M., Yandle T. G., Espiner E. A., Nicholls M. G., Richards A. M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N‐BNP) concentrations. Lancet 2000; 355: 1126–30
   PubMed Web of Science ®Google Scholar
• Jourdain P., Funck F., Gueffet P., Lehelloco H., Donal E., Aupetit J. F. Benefit of BNP plasma levels for optimising therapy: the Systolic Heart Failure Treatment Supported by BNP Multicenter Randomised Trial (STARS‐BNP). J Am Coll Cardiol 2005; 45((suppl. A))3A (abstract 1001–151)
   Google Scholar
• Mcdonagh T. A., Robb S. D., Murdoch D. R., Morton J. J., Ford I., Morrison C. E. Biochemical detection of left‐ventricular systolic dysfunction. Lancet 1998; 351: 9–13
   PubMed Web of Science ®Google Scholar
• Nielsen O. W., Mcdonagh T. A., Robb S. D., Dargie H. J. Retrospective analysis of the cost‐effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41: 113–120
   PubMed Web of Science ®Google Scholar
• Heidenreich P. A., Gubens M. A., Fonarow G. C., Konstam M. A., Stevenson L. W., Shekelle P. G. Cost effectiveness of screening with B‐type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004; 43: 1019–1026
   PubMed Web of Science ®Google Scholar
• Logeart D., Thabut G., Jourdain P., Chavelas C., Beyne P., Beauvais F. Pre‐discharge B‐type natriuretic peptide assay for identifying patients at high risk of readmission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635–641
   PubMed Web of Science ®Google Scholar